Glycemic Variability (GV) and Treatment Satisfaction (TS) are not accurately reflected in HbA1c. This study explored GV measures and their effect on insulin TS, productivity and activity in a real-world population with T1D. This prospective survey was of 98 adults from the T1D Exchange online patient community. Surveys were completed and CGM data were downloaded at baseline and weekly thereafter for 4 weeks (week). The Insulin Treatment Satisfaction Questionnaire was done at week 4, and Work Productivity Impairment (WPI) and Activity Impairment (AI)-General Health Questionnaire were done weekly for 4 weeks. Linear regression and mixed models explored the relationship between GV and TS, and impairment, respectively. Overall mean age was 43 years (SD 15.3), mean years with T1D was 22 (SD 14.2), 68% were female, and mean self-reported most recent HbA1c was 6.8% (SD 0.8). Participants on insulin pump (n=86) and multiple daily injections (n=12) took an average of 47.7 Units (±35.8) and 39.3 Units (±23.1) of insulin, respectively. Markers of GV and patient reported measures are in Table. Of the 14 GV measures examined, CV and LBGI showed a positive association with insulin TS (p<.05). No GV measures significantly impacted WPI or AI. The adult population with T1D in this survey had high TS, and had low WPI and AI, despite overall moderate risk for hypoglycemia.


L. Fan: Employee; Self; Eli Lilly and Company. C. Garey: None. J. Liu: None. B. Mitchell: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. J. Bispham: None. A.H. McAuliffe-Fogarty: Advisory Panel; Self; Novo Nordisk Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at